Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which sedation is safer for TAVR? propofol vs dexmedetomidine

NCT ID NCT05462938

Knowledge-focused Sponsor: University of Ioannina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two common sedation drugs, propofol and dexmedetomidine, in 65 older adults undergoing a less invasive heart valve replacement called TAVR. The goal was to see which drug leads to better kidney function, less confusion, and fewer complications after the procedure. Researchers measured kidney markers and delirium at several time points up to 30 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
propofol and dexmedetomidine
What this could lead to
If this study shows one drug is clearly better, it could guide doctors to choose the safer sedation method for TAVR patients, potentially reducing kidney problems and confusion after the procedure.
What could go wrong
This is a small, completed study with only 65 patients, so results may not apply to everyone. The findings are not yet conclusive and need larger trials to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

65 people

The number who actually took part.

Started

Nov 2021

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients scheduled for TAVR Exclusion Criteria: * Emergency operation * Pre-existing neurocognitive dysfunction (Mini Mental State Examination score \<23) * Inability to cooparate - communicate * End Stage Renal Disease * Allergy to any of the administrated drugs * No consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse event are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve stenosis Death Emergence Delirium impaired renal function disease Personal Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse event Death Postoperative delirium Renal function disorder Satisfaction

Contacts and locations

Locations

  • Univesity Hospital of Ioannina

    Ioannina, Epirus, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.